We are grateful for external funding from The Research Council of Norway, Norwegian Cancer Society, South-Eastern Norway Regional Health Authority and EU.
Laursen MF, Combes F, Gudjonsson A, Bjerkan L, Parot J, Tesfaye DY, Pettersson FJ, Molska A, Visweswaran GRR, Labbé GM, Draper SJ, Borgos SE, Bogen B, Braathen R(2026) Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines Mol Ther(in press) DOI 10.1016/j.ymthe.2026.06.034, PubMed 42363600
Harvey R, Welsh C, Byrne AM, Greenwood D, Stevenson-Leggett P, Galiano M, Bailey D, Chan YW, Boateng J, Wolmuth-Gordon H, Whitaker H, Brown KE, Jeffery-Smith A, Allen A, Amirthanlingam G, Fossum E, Vikse EL, Rohringer A, Hungnes O, Bragstad K, Swanton C, Williams B, Gandhi S, Gamblin S, Carr EJet al.(2026) Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence EBioMedicine, 129, 106332 DOI 10.1016/j.ebiom.2026.106332, PubMed 42276011
Robertson AH, Wolf AS, Fossum E, Solum G, Bhandari S, Vikse EL, Kjønstad IF, Magnus P, Nygaard UC, Lund-Johansen F, Trogstad L, Mjaaland S(2026) Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections Vaccine, 80, 128511 DOI 10.1016/j.vaccine.2026.128511, PubMed 41895154
